FDA Clears Rasonque for Pancreatic Cancer at $477,000 a Year
FDA Approves Revolution Medicines' Rasonque for Pancreatic Cancer, Priced at $477,000 AnnuallyThe New York Times77d ago F.D.A. Approves Daraxonrasib (Rasonque) for Pancreatic Cancer, Targeting KRAS ProteinFDA Approves Rasonque for Advanced Pancreatic Cancer, Nearly Doubling SurvivalThe New York Times78d ago F.D.A. Approves Daraxonrasib for Advanced Pancreatic Cancer, Extending Patient LivesThe Washington Post78d ago FDA Approves Revolution Medicines' Daraxonrasib for Pancreatic CancerFDA Approves Daraxonrasib for Pancreatic Cancer After Breakthrough Trial ResultsTwo New Drugs Offer Hope for Pancreatic CancerFDA approves Rasonque, pancreatic cancer drug expected to extend livesThe Associated Press78d ago FDA Approves Daraxonrasib for Advanced Pancreatic Cancer, Doubling SurvivalFDA Approves Daraxonrasib for Pancreatic Cancer, Developed by Dana-FarberFDA Approves Revolution Medicines' Rasonque for Metastatic Pancreatic CancerFDA Approves Daraxonrasib (Rasonque) for Advanced Metastatic Pancreatic CancerRevolution Medicines wins FDA approval for Rasonque, the first drug to target the genetic driver of pancreatic cancer | Dealroom.coFDA Approves Daraxonrasib for Previously Treated Metastatic Pancreatic Cancer | CancerNetworkFDA Allows Expanded Access to Daraxonrasib for PDAC | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer PathwaysRevolution Medicines drug daraxonrasib doubles pancreatic cancer survival time - DongA SciencePredicting How Today's FDA Approval of Zanidatamab Will Affect Gastric Cancer CarePancreatic cancer is one of the deadliest and most difficult cancers to treat. The University of Chicago Medicine is now offering a new oral medication that can help extend patients' lives. OncologistFDA Approves Revolution Medicines' Rasonque for Metastatic Pancreatic CancerFDA Approves Rasonque for Advanced Pancreatic Cancer